{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:00:42Z","timestamp":1760043642783},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1097\/mjt.0b013e3181d48320","type":"journal-article","created":{"date-parts":[[2010,3,24]],"date-time":"2010-03-24T08:15:25Z","timestamp":1269418525000},"page":"300-304","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of Short-Acting Intramuscular Antipsychotic Medication: Impact on Length of Stay and Cost"],"prefix":"10.1097","volume":"18","author":[{"given":"Jonathan G","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda M","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A","family":"Frazee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Myers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-6-20210202","first-page":"41","article-title":"Treatment Adherence.","volume":"12","author":"Moosa","year":"2007","journal-title":"SAJP"},{"key":"R2-6-20210202","doi-asserted-by":"crossref","first-page":"42","DOI":"10.2146\/ajhp060635","article-title":"Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia.","volume":"65","author":"Strutton","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"S10","key":"R3-6-20210202","first-page":"13","article-title":"A review of agitation in mental illness: treatment guidelines and current therapies.","volume":"67","author":"Marder","year":"2006","journal-title":"J Clin Psychol"},{"key":"R4-6-20210202","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.4088\/JCP.v66n0906","article-title":"The economic burden of schizophrenia in the United States in 2002.","volume":"66","author":"Wu","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"S3","key":"R5-6-20210202","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0924-977X(00)80322-3","article-title":"Impact of early intervention with intramuscular antipsychotic medication in an acute care setting.","volume":"10","author":"Martinez","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"R6-6-20210202","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003495-200363050-00004","article-title":"Intramuscular preparations of antipsychotics.","volume":"63","author":"Altamura","year":"2003","journal-title":"Drugs"},{"key":"R7-6-20210202","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2165\/00023210-200519020-00005","article-title":"Intramuscular olanzapine.","volume":"19","author":"Wagstaff","year":"2005","journal-title":"CNS Drugs"},{"key":"R8-6-20210202","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/00003088-200544110-00002","article-title":"Pharmacokinetics and therapeutics of acute intramuscular ziprasidone.","volume":"44","author":"Preskorn","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R9-6-20210202","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1345\/aph.1E258","article-title":"Intramuscular olanzapine in the management of acute agitation.","volume":"38","author":"Tulloch","year":"2004","journal-title":"Ann Pharmacother"},{"key":"R10-6-20210202","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.59.5.441","article-title":"A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia.","volume":"59","author":"Breier","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"R11-6-20210202","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1177\/070674370304801102","article-title":"Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during during the first 24 hours of treatment.","volume":"48","author":"Wright","year":"2003","journal-title":"Can J Pyschiatry"},{"key":"R12-6-20210202","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4088\/JCP.v61n1208","article-title":"Ziprasidone IM study group. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis.","volume":"61","author":"Brooks","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R13-6-20210202","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-006-0541-x","article-title":"Intramuscular aripiprazole for the treatment of acute agitation in patient with schizophrenia or schizoaffective disorder.","volume":"188","author":"Andrezina","year":"2006","journal-title":"Psychopharmacology"},{"key":"R14-6-20210202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v68n0115","article-title":"Efficacy and safety of aripiprazole in patients with acute agitation.","volume":"68","author":"Tran-Johnson","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R15-6-20210202","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.4088\/JCP.v68n1207","article-title":"Comparison of intramuscluar ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety.","volume":"68","author":"Citrome","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"R17-6-20210202","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0735-6757(97)90119-4","article-title":"Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study.","volume":"15","author":"Battaglia","year":"1997","journal-title":"Am J Emerg Med"},{"key":"R18-6-20210202","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1176\/ajp.146.12.1598","article-title":"Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation.","volume":"146","author":"Garza-Trevino","year":"1989","journal-title":"Am J Psychiatry"},{"key":"R19-6-20210202","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/emj.20.4.339","article-title":"Pharmacological management of agitation n emergency settings.","volume":"20","author":"Yildiz","year":"2003","journal-title":"Emerg Med J"},{"key":"R20-6-20210202","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2165\/00003495-200565090-00003","article-title":"Pharmacological management of acute agitation.","volume":"65","author":"Battaglia","year":"2005","journal-title":"Drugs"},{"key":"R21-6-20210202","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.2146\/ajhp070460","article-title":"Optimizing patient safety by combined use of intramuscular olanzapine and parenteral benzodiazaines.","volume":"65","author":"Naso","year":"2008","journal-title":"Am J Health -Syst Pharm"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MJT.0b013e3181d48320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:35:43Z","timestamp":1620963343000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-201107000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181d48320","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7]]}}}